Header Logo

Connection

AMAN U BUZDAR to Receptors, Estrogen

Back to Details
This is a "connection" page, showing publications AMAN U BUZDAR has written about Receptors, Estrogen.
AMAN U BUZDAR
Connection Strength
1.835
Receptors, Estrogen
  1. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008 Mar 01; 26(7):1059-65.
    View in: PubMed
    Score: 0.184
  2. Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer. Drugs Today (Barc). 2004 Sep; 40(9):751-64.
    View in: PubMed
    Score: 0.146
  3. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women. Breast J. 2004 May-Jun; 10(3):211-7.
    View in: PubMed
    Score: 0.142
  4. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017 Apr 01; 35(10):1049-1060.
    View in: PubMed
    Score: 0.086
  5. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1013s-1018s.
    View in: PubMed
    Score: 0.080
  6. Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. Clin Cancer Res. 2015 Jun 15; 21(12):2763-70.
    View in: PubMed
    Score: 0.077
  7. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014 May; 25(5):1004-11.
    View in: PubMed
    Score: 0.070
  8. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer. 1992 Jan 15; 69(2):448-52.
    View in: PubMed
    Score: 0.061
  9. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011 Nov 10; 29(32):4273-8.
    View in: PubMed
    Score: 0.060
  10. Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol. 2009 Jun; 20(6):993-9.
    View in: PubMed
    Score: 0.049
  11. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol. 2007 May; 18(5):874-80.
    View in: PubMed
    Score: 0.043
  12. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer. 2006 May 15; 106(10):2095-103.
    View in: PubMed
    Score: 0.041
  13. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006 Mar 01; 24(7):1037-44.
    View in: PubMed
    Score: 0.040
  14. Are aromatase inhibitors superior to antiestrogens? J Steroid Biochem Mol Biol. 2005 Feb; 93(2-5):237-47.
    View in: PubMed
    Score: 0.037
  15. How rapidly do oncologists respond to clinical trial data? Oncologist. 2005 Jan; 10(1):15-21.
    View in: PubMed
    Score: 0.037
  16. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2004 Feb; 4(6):415-9.
    View in: PubMed
    Score: 0.035
  17. Breast cancer in men. Oncology (Williston Park). 2003 Oct; 17(10):1361-4; discussion 1364, 1369-72.
    View in: PubMed
    Score: 0.034
  18. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):1007-14.
    View in: PubMed
    Score: 0.033
  19. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat. 2003 Mar; 78(1):105-18.
    View in: PubMed
    Score: 0.033
  20. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s.
    View in: PubMed
    Score: 0.030
  21. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001 Nov 01; 92(9):2247-58.
    View in: PubMed
    Score: 0.030
  22. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 2001 Jul 15; 19(14):3357-66.
    View in: PubMed
    Score: 0.029
  23. Tamoxifen's clinical applications: old and new. Arch Fam Med. 2000 Sep-Oct; 9(9):906-12.
    View in: PubMed
    Score: 0.028
  24. Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2. Clin Pharmacol Ther. 2019 07; 106(1):219-227.
    View in: PubMed
    Score: 0.025
  25. The place of chemotherapy in the treatment of early breast cancer. Br J Cancer. 1998 Sep; 78 Suppl 4:16-20.
    View in: PubMed
    Score: 0.024
  26. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Res Treat. 2016 08; 159(1):109-18.
    View in: PubMed
    Score: 0.021
  27. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1049s-1055s.
    View in: PubMed
    Score: 0.020
  28. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res. 2015 Apr 16; 17:56.
    View in: PubMed
    Score: 0.019
  29. Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study. Breast Cancer Res Treat. 2013 Jul; 140(2):253-62.
    View in: PubMed
    Score: 0.017
  30. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol. 2012 Jun; 23(6):1378-86.
    View in: PubMed
    Score: 0.015
  31. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011 May 20; 29(15):1956-62.
    View in: PubMed
    Score: 0.014
  32. Predictive algorithms for adjuvant therapy: TransATAC. Steroids. 2011 Jul; 76(8):777-80.
    View in: PubMed
    Score: 0.014
  33. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol. 1990 Jul; 8(7):1207-16.
    View in: PubMed
    Score: 0.014
  34. Measurement of estrogen and progesterone receptors in human breast tumors: enzyme immunoassay versus binding assay. J Clin Oncol. 1990 Jun; 8(6):1025-35.
    View in: PubMed
    Score: 0.014
  35. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res. 2010 Apr 15; 70(8):3278-86.
    View in: PubMed
    Score: 0.013
  36. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med. 1988 12 29; 319(26):1681-92.
    View in: PubMed
    Score: 0.012
  37. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. Cancer. 1988 Nov 15; 62(10):2098-104.
    View in: PubMed
    Score: 0.012
  38. Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer. Cancer. 1988 Nov 15; 62(10):2105-10.
    View in: PubMed
    Score: 0.012
  39. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol. 2008 Dec; 19(12):2020-5.
    View in: PubMed
    Score: 0.012
  40. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998 May 16; 351(9114):1451-67.
    View in: PubMed
    Score: 0.012
  41. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008 Apr 01; 26(10):1664-70.
    View in: PubMed
    Score: 0.012
  42. Complete remission with combination chemotherapy in metastatic breast carcinoma. Am J Clin Oncol. 1986 Aug; 9(4):361-3.
    View in: PubMed
    Score: 0.010
  43. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):997s-1000s.
    View in: PubMed
    Score: 0.010
  44. Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986; (1):81-5.
    View in: PubMed
    Score: 0.010
  45. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer. 2005 Sep 15; 104(6):1158-71.
    View in: PubMed
    Score: 0.010
  46. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer. 2005 Jun 15; 103(12):2466-72.
    View in: PubMed
    Score: 0.010
  47. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. Clin Cancer Res. 2005 Jan 01; 11(1):315-22.
    View in: PubMed
    Score: 0.009
  48. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. Semin Oncol. 1984 Sep; 11(3 Suppl 1):28-31.
    View in: PubMed
    Score: 0.009
  49. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1337-42.
    View in: PubMed
    Score: 0.009
  50. Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):327S-330S.
    View in: PubMed
    Score: 0.009
  51. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer. 2003 Jun 01; 97(11):2716-23.
    View in: PubMed
    Score: 0.008
  52. Estrogen receptor: a prognostic factor in breast cancer. Cancer. 1981 Feb 01; 47(3):554-60.
    View in: PubMed
    Score: 0.007
  53. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer. 2000 May 01; 88(9):2054-60.
    View in: PubMed
    Score: 0.007
  54. Hormone receptors in breast cancer and response to chemotherapy. N Engl J Med. 1979 May 03; 300(18):1053.
    View in: PubMed
    Score: 0.006
  55. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm. 1996 Aug; 11(4):235-45.
    View in: PubMed
    Score: 0.005
  56. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer. 1994 Apr 15; 73(8):2157-67.
    View in: PubMed
    Score: 0.004
  57. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci. 1994; 55(1):53-67.
    View in: PubMed
    Score: 0.004
  58. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer. 1990 Feb 15; 65(4):847-50.
    View in: PubMed
    Score: 0.003
  59. Sequential cyclic combined hormonal therapy for metastatic breast cancer. Cancer. 1989 Sep 01; 64(5):1002-6.
    View in: PubMed
    Score: 0.003
  60. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988 Dec 15; 62(12):2507-16.
    View in: PubMed
    Score: 0.003
  61. Trioxifene mesylate in the treatment of advanced breast cancer. Cancer. 1986 Jan 01; 57(1):40-3.
    View in: PubMed
    Score: 0.002
  62. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1985; 5(3):321-6.
    View in: PubMed
    Score: 0.002
  63. The management of locally advanced breast cancer: a combined modality approach. Eur J Cancer Clin Oncol. 1984 Nov; 20(11):1353-61.
    View in: PubMed
    Score: 0.002
  64. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA. 1983 Apr 08; 249(14):1881-6.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.